

## **CLAIMS**

### **FORMULATIONS THAT CONTAIN AGENTS OF THROMBOLYTIC ACTION FOR RECTAL ADMINISTRATION**

1. Formulations that contain agents of thrombolytic action for their administration via rectal
  - Proteins and peptides with active thrombolytic and pharmacologically action.
  - Oil Base.
  - Active substances as: absorption promoters, protease inhibitors and preservers.
2. One formulation that according to claim 1 characterized for containing proteins with thrombolytic action and/or anti-inflammatory, as streptokinase, (urokinase) and/or tissue activator of plasminogen.
3. One formulation that according to claim 1 characterized for containing recombinant streptokinase in a concentration of 50 000 – 1.500.000 UI/g.
4. One formulation that according to claim 1 characterized for containing natural streptokinase in a concentration of 50 000 – 1.500.000 UI/g.
5. One formulation that according to claim 1 characterized for containing urokinase in a concentration of 50 000 - 1.000.000 UI/g
6. One formulation that according to claim 1 characterized for containing tissue plasminogen activator in a concentration of 500000-50000000 UI/g.
7. One formulation that according to claim 1- 6 characterized for containing promoters of mucosal absorption like sodium diclofenac and/or sodium salicylate.
8. One formulation that according to claim 1- 6 characterized for containing protease inhibitor.

9. One formulation that according to claim 8 characterized because the protease inhibitor is EDTA.
10. One formulation that according to claims 1-7, 8 y 9 characterized because the oil base is Witepsol H15.
11. One formulation that according to claims 1-10 characterized because the median weigh of the suppository is 1-3 g.
12. One formulation that according to claims 1-11 characterized for been efficacious, without systemic effects for the treatment of hemorrhoidal disease.
13. A method for the treatment of hemorrhoids characterized by the use of proteins and peptides with thrombolytic action via rectal in a suppository formulation .
14. One method that according to claim 13 characterized because the protein with thrombolyticaction is streptokinase or peptides derivates from her.
15. One method that according to claim 13 characterized because the protein with thrombolytic action is (urokinase) or peptides derive from her.
16. One method that according to claim 13 characterized because the protein with thrombolyticaction is the tissue plasminogen activator of or peptides derive from it.
17. The use of protein and peptides with thrombolyticaction for the treatment of hemorrhoids characterized by it use via rectal and in a suppository formulation.
18. The use according to tclaim 17 where the protein with thrombolytic action is streptokinase or peptides derive from her for the treatment of hemorrhoids characterized by it use via rectal and in a suppository formulation.

19. The use according to claim 17 where the protein with thrombolytic action is (urokinase) or peptides derive from it for the treatment of hemorrhoids characterized by her use via rectal and in a suppository formulation.
20. The use according to claim 17 where the protein with thrombolytic action is the tissue plasminogen activator or peptides derive from it for the treatment of hemorrhoids characterized by it use via rectal and in a suppository formulation.